GLP-1 Market Analysis Includes Managed Medicaid Claims Data on Utilization Patterns

Avalere analyzed pharmacy claims across payer types including Managed Medicaid to assess on-label and off-label use of GLP-1 and GIP/GLP-1 receptor agonists for diabetes and weight management. The piece examines product differentiation strategies for manufacturers and notes that USP Drug Classification limitations affect coverage decisions in non-Part D plans. While focused primarily on manufacturer strategy and market dynamics, the analysis incorporates Medicaid managed care data and touches on formulary implications relevant to MCO pharmacy benefit management.

Pharmacy · Managed Care

This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.

More from Avalere